TREK-1 is a novel molecular target in prostate cancer

Iryna Voloshyna1, Alessandra Besana, Mireia Castillo

  • 1Department of Pharmacology, Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York 10032, USA.

Cancer Research
|February 19, 2008
PubMed

Insights

TREK-1 potassium channels are highly expressed in prostate cancer, driving abnormal cell proliferation. Inhibiting TREK-1 may offer a new therapeutic target for prostate cancer treatment.

Area of Science:

  • Molecular Biology
  • Oncology
  • Physiology

Background:

  • Potassium channels, specifically two-pore domain (K2P) channels, are implicated in cell proliferation.
  • Some K2P channels, like TASK-3, are overexpressed in neoplasms, suggesting a role in cancer.

Purpose of the Study:

  • To investigate the expression of TREK-1 in prostate tissues and cell lines.
  • To determine the role of TREK-1 in prostate cancer cell proliferation.

Main Methods:

  • Quantitative analysis of TREK-1 expression in normal prostate, benign prostatic hyperplasia, and prostate cancer tissues.
  • In vitro studies using prostate cancer cell lines (PC3, LNCaP) and normal prostate epithelial cells (NPE).
  • Functional assays involving TREK-1 overexpression, dominant-negative mutants, and pharmacological inhibitors.

Main Results:

  • TREK-1 is highly expressed in prostate cancer but not in normal or benign prostate tissues.
  • TREK-1 expression correlates with advanced disease grade and stage.
  • Overexpression of TREK-1 significantly increases proliferation in NPE and CHO cells.
  • Inhibition of TREK-1 activity reduces proliferation in prostate cancer cells.

Conclusions:

  • TREK-1 expression is associated with abnormal cell proliferation in prostate cancer.
  • TREK-1 may serve as a novel biomarker for prostate cancer.
  • TREK-1 represents a potential molecular target for prostate cancer therapy.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...